China Digest: Sansheng, WeShine and OPM Biosciences snag funds

Sansheng, a Chinese provider of reproductive hormones for fish and livestock, has raised nearly 200 million yuan ($29 million), while Tencent-backed SaaS startup WeShine has completed a Series A round of financing led by Sequoia Capital China. Meanwhile, Chinese biotech firm Shanghai OPM Biosciences has closed a Series B round led by Chinese alternative asset management arm CPE.